Satralizumab 120 mg
ApprovedTerminated 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Neuromyelitis Optica Spectrum Disorder
Conditions
Neuromyelitis Optica Spectrum Disorder, NMOSD
Trial Timeline
Aug 2, 2022 → Oct 26, 2023
NCT ID
NCT05269667About Satralizumab 120 mg
Satralizumab 120 mg is a approved stage product being developed by Chugai Pharmaceutical for Neuromyelitis Optica Spectrum Disorder. The current trial status is terminated. This product is registered under clinical trial identifier NCT05269667. Target conditions include Neuromyelitis Optica Spectrum Disorder, NMOSD.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05269667 | Approved | Terminated |
Competing Products
8 competing products in Neuromyelitis Optica Spectrum Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Satralizumab + Placebo + Baseline Treatment | Chugai Pharmaceutical | Phase 3 | 77 |
| Satralizumab + Placebo | Chugai Pharmaceutical | Phase 3 | 77 |
| satralizumab + azathioprine (AZA) + mycophenolate mofetil (MMF) + oral corticosteroids | Roche | Phase 3 | 77 |
| Satralizumab | Roche | Phase 3 | 77 |
| UPLIZNA | Amgen | Pre-clinical | 22 |
| Inebilizumab | Amgen | Phase 2 | 51 |
| Inebilizumab | Amgen | Approved | 84 |
| intravenous methylprednisolone | Brain Biotech | Pre-clinical | 15 |